XBiotech, Inc.

Johnson & Johnson unveiled its second atopic dermatitis-focused deal this month on 28 May, paying $1.25bn in cash to acquire a subsidiary of Numab Therapeutics AG that houses a Phase II-ready bispe

Johnson & Johnson has made a major push with its immunology portfolio even as its mature Remicade (infliximab) franchise began to wane and faced biosimilar competition. CEO Alex Gorsky cited the immu

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Roche Pays Rheos $42.5m Up F

Third Rock Ventures LLC launched more than 50 biopharma, device and diagnostic companies with its first four venture capital funds, and with its fifth and largest – the $770m Third Rock Ventures V LP